Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells

J Li, 2010, Pancreatic cancer: pathobiology, treatment options, and drug delivery., AAPS J, 12, 223, 10.1208/s12248-010-9181-5

M Inui, 2010, MicroRNA control of signal transduction., Nat Rev Mol Cell Biol, 11, 252, 10.1038/nrm2868

S Sharma, 2010, Epigenetics in cancer., Carcinogenesis, 31, 27, 10.1093/carcin/bgp220

R Schickel, 2008, MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death., Oncogene, 27, 5959, 10.1038/onc.2008.274

E Bandres, 2007, MicroRNAs as cancer players: potential clinical and biological effects., DNA Cell Biol, 26, 273, 10.1089/dna.2006.0544

R Garzon, 2009, MicroRNAs in Cancer., Annu Rev Med, 60, 167, 10.1146/annurev.med.59.053006.104707

YS Lee, 2009, MicroRNAs in cancer., Annu Rev Pathol, 4, 199, 10.1146/annurev.pathol.4.110807.092222

S Baranwal, 2010, miRNA control of tumor cell invasion and metastasis., Int J Cancer, 126, 1283, 10.1002/ijc.25014

PM Voorhoeve, 2010, MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity?, Biochim Biophys Acta, 1805, 72

MS Nicoloso, 2009, MicroRNAs—the micro steering wheel of tumour metastases., Nat Rev Cancer, 9, 293, 10.1038/nrc2619

SA Waldman, 2007, Translating MicroRNA discovery into clinical biomarkers in cancer., JAMA, 297, 1923, 10.1001/jama.297.17.1923

J Wang, 2009, MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease., Cancer Prev Res (Phila Pa), 2, 807, 10.1158/1940-6207.CAPR-09-0094

CL Bartels, 2009, MicroRNAs: novel biomarkers for human cancer., Clin Chem, 55, 623, 10.1373/clinchem.2008.112805

CL Bartels, 2010, [MicroRNAs: novel biomarkers for human cancer]., Ann Biol Clin (Paris), 68, 263

JF Wiggins, 2010, Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34., Cancer Res, 70, 5923, 10.1158/0008-5472.CAN-10-0655

CM Croce, 2005, miRNAs, cancer, and stem cell division., Cell, 122, 6, 10.1016/j.cell.2005.06.036

S Shankar, 2011, Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition., PLoS One, 6, e16530, 10.1371/journal.pone.0016530

C Li, 2009, Identification of human pancreatic cancer stem cells., Methods Mol Biol, 568, 161, 10.1007/978-1-59745-280-9_10

H Immervoll, 2008, Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas., BMC Cancer, 8, 48, 10.1186/1471-2407-8-48

TC Chang, 2007, Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis., Mol Cell, 26, 745, 10.1016/j.molcel.2007.05.010

JP Morton, 2008, Trp53 deletion stimulates the formation of metastatic pancreatic tumors., Am J Pathol, 172, 1081, 10.2353/ajpath.2008.070778

JP Morton, 2010, Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer., Proc Natl Acad Sci U S A, 107, 246, 10.1073/pnas.0908428107

A Bergan, 2000, p53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head., Int J Oncol, 17, 921

YX Hu, 1999, Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma., Br J Cancer, 80, 1075, 10.1038/sj.bjc.6690466

H Kawahira, 2000, p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy., Hepatogastroenterology, 47, 973

N Raver-Shapira, 2007, Transcriptional activation of miR-34a contributes to p53-mediated apoptosis., Mol Cell, 26, 731, 10.1016/j.molcel.2007.05.017

C Welch, 2007, MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells., Oncogene, 26, 5017, 10.1038/sj.onc.1210293

D Lodygin, 2008, Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer., Cell Cycle, 7, 2591, 10.4161/cc.7.16.6533

CS Chim, 2010, Epigenetic inactivation of the miR-34a in hematological malignancies., Carcinogenesis, 31, 745, 10.1093/carcin/bgq033

DC Corney, 2010, Frequent downregulation of miR-34 family in human ovarian cancers., Clin Cancer Res, 16, 1119, 10.1158/1078-0432.CCR-09-2642

L He, 2007, microRNAs join the p53 network—another piece in the tumour-suppression puzzle., Nat Rev Cancer, 7, 819, 10.1038/nrc2232

ME Mullendore, 2009, Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer., Clin Cancer Res, 15, 2291, 10.1158/1078-0432.CCR-08-2004

OJ De La, 2009, Notch signaling: where pancreatic cancer and differentiation meet?, Gastroenterology, 136, 1499, 10.1053/j.gastro.2009.03.022

K Yoon, 2005, Notch signaling in the mammalian central nervous system: insights from mouse mutants., Nat Neurosci, 8, 709, 10.1038/nn1475

SJ Bray, 2006, Notch signalling: a simple pathway becomes complex., Nat Rev Mol Cell Biol, 7, 678, 10.1038/nrm2009

T Iso, 2003, HES and HERP families: multiple effectors of the Notch signaling pathway., J Cell Physiol, 194, 237, 10.1002/jcp.10208

O Basak, 2007, Identification of self-replicating multipotent progenitors in the embryonic nervous system by high Notch activity and Hes5 expression., Eur J Neurosci, 25, 1006, 10.1111/j.1460-9568.2007.05370.x

N Takebe, 2011, Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways., Nat Rev Clin Oncol, 8, 97, 10.1038/nrclinonc.2010.196

M Katoh, 2006, Notch ligand, JAG1, is evolutionarily conserved target of canonical WNT signaling pathway in progenitor cells., Int J Mol Med, 17, 681

Z Wang, 2011, Pancreatic cancer: understanding and overcoming chemoresistance., Nat Rev Gastroenterol Hepatol, 8, 27, 10.1038/nrgastro.2010.188

JR O'Rourke, 2006, MicroRNAs in mammalian development and tumorigenesis., Birth Defects Res C Embryo Today, 78, 172, 10.1002/bdrc.20071

S Volinia, 2006, A microRNA expression signature of human solid tumors defines cancer gene targets., Proc Natl Acad Sci U S A, 103, 2257, 10.1073/pnas.0510565103

TE Fandy, 2005, Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma., Neoplasia, 7, 646, 10.1593/neo.04655

S Shankar, 2009, Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice., Mol Cancer Ther, 8, 1596, 10.1158/1535-7163.MCT-08-1004

AS Azmi, 2010, Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy., Curr Cancer Drug Targets, 10, 319, 10.2174/156800910791190229

M Yamakuchi, 2009, MiR-34, SIRT1 and p53: the feedback loop., Cell Cycle, 8, 712, 10.4161/cc.8.5.7753

Y Fujita, 2008, Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells., Biochem Biophys Res Commun, 377, 114, 10.1016/j.bbrc.2008.09.086

U Koch, 2007, Notch and cancer: a double-edged sword., Cell Mol Life Sci, 64, 2746, 10.1007/s00018-007-7164-1

K Kimura, 2007, Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice., Cancer Sci, 98, 155, 10.1111/j.1349-7006.2006.00369.x

P Buchler, 2005, The Notch signaling pathway is related to neurovascular progression of pancreatic cancer., Ann Surg, 242, 791, 10.1097/01.sla.0000189115.94847.f1

S Shankar, 2005, Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways., Int J Mol Med, 16, 1125

S Shankar, 2007, Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer., Front Biosci, 12, 5039, 10.2741/2446